Hinge Health's Bullish Outlook
Hinge Health Raises 2026 Revenue and Profit Guidance, Stifel Boosts Price Target
Key Points
Insider selling was quantified: insiders sold about $29.9 million worth of Hinge Health shares over the prior three months, with “no purchases reported.”
Hinge Health’s raised outlook included more specific non-GAAP profitability targets: it forecast non-GAAP operating income of $50 million to $52 million for Q2 2026 (about 25% non-GAAP operating margin at the midpoint) and $217 million to $227 million for full-year 2026 (27% at the midpoint).
Stifel said its $79 price target (up from $67) was driven not only by Hinge Health’s results and AI platform, but also by “recent investor meetings with Hinge Health management” and a “proprietary benefit manager survey” pointing to strong client acquisition and retention momentum.
Investor Day details were specific: Hinge Health’s first Investor Day is scheduled for June 10, 2026, at the company’s Movement conference, and the event will be webcast with a replay available for 12 months.
Hinge Health raised its 2026 revenue guidance on June 10, forecasting full-year revenue of $818 million to $824 million — a roughly 40% jump year-over-year — along with a non-GAAP operating margin of 27% at the midpoint, according to TipRanks. The company made the announcement at its first-ever Investor Day, held at its Movement conference in San Francisco.
The updated outlook also covers Q2 2026 specifically, with revenue expected between $200 million and $202 million, well above the prior analyst consensus of roughly $195 million, TipRanks reported. The company credited stronger member conversion and better client performance, powered by its AI-enabled platform for treating joint and muscle pain.
Profitability Targets Jump as AI Cuts Costs
Hinge Health also raised its non-GAAP operating income targets sharply. It now expects $50 million to $52 million in Q2 operating income — about a 25% margin — and $217 million to $227 million for the full year, implying a 27% margin at the midpoint, per TipRanks. Those figures are up from a prior range of roughly 19% to 21%.
The margin expansion is tied to what the company calls "asynchronous" care — physical therapy guidance delivered through an app, not a live video call. CEO Daniel Perez said AI now handles about 80% of routine protocol adjustments, leaving human clinicians for complex cases only. "Our margin profile mirrors a pure-play software company rather than a traditional healthcare provider," Perez said at the Investor Day keynote, according to Quartr.
Stifel Raises Price Target to $79 After Investor Meetings
Stifel analyst Scott Devitt raised his price target on Hinge Health from $67 to $79 the day after Investor Day, maintaining a Buy rating. He cited not just the updated numbers, but also "recent investor meetings with Hinge Health management" and a proprietary survey of 150 benefits managers, according to GuruFocus.
Devitt's survey found that 82% of HR managers plan to increase digital health spending for musculoskeletal care in 2027, with Hinge listed as the preferred vendor in 68% of those cases. He argued that 2026 and 2027 growth could outpace Wall Street consensus, driven by strong client acquisition and retention. Stifel said retention rates exceed 95%, calling Hinge a "sticky" incumbent in the space.
Insiders Sold $29.9 Million in Shares — With Zero Purchases
Despite the upbeat outlook, insiders sold roughly $29.9 million worth of Hinge Health shares over the prior three months, with no open-market purchases reported during that period, according to TipRanks. The sellers include executives and board members, with filings showing a consistent pattern of divestment from March through May 2026.
The company has framed the selling as routine liquidity following a lock-up period. But critics argue the timing raises questions. Some analysts noted that if the AI platform is as transformative as management claims, insiders would typically be buying, not selling. The divergence between bullish guidance and insider behavior has become a point of debate heading into Q2 earnings in August.
Investor Day Sets Stage for a $824 Million Year
Hinge Health's Investor Day on June 10 was its first ever. The event was webcast live, with a replay available for 12 months through the company's investor relations page, per TipRanks. The presentation focused heavily on the AI-enabled care model and how automating routine therapy adjustments has decoupled revenue growth from clinical headcount.
Co-founder and Executive Chairman Gabriel Bratton emphasized that AI is not replacing clinicians. "The AI isn't replacing the clinician; it's extending their reach by a factor of ten," he said, according to Quartr. All eyes now shift to the Q2 earnings call in August, where the company will need to hit at least $200 million in revenue to validate the raised guidance — and quiet concerns about the insider selling.
Sentiment
Mostly PositivePublishers
11
Articles
15
Reach
26
